Last reviewed · How we verify
SAR441566
At a glance
| Generic name | SAR441566 |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. (PHASE2)
- A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis (PHASE2)
- A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants. (PHASE1)
- A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) (PHASE2)
- A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis (PHASE2)
- A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis (PHASE1)
- A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants. (PHASE1)
- A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAR441566 CI brief — competitive landscape report
- SAR441566 updates RSS · CI watch RSS
- Sanofi portfolio CI